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Trafficking of AMPA receptors (AMPARs) is reg-
ulated by specific interactions of the subunit
intracellular C-terminal domains (CTDs) with
other proteins, but the mechanisms involved
in this process are still unclear. We have found
that the GluR1 CTD binds to cGMP-dependent
protein kinase II (cGKII) adjacent to the kinase
catalytic site. Binding of GluR1 is increased
when cGKII is activated by cGMP. cGKII and
GluR1 form a complex in the brain, and cGKII
in this complex phosphorylates GluR1 at S845,
a site also phosphorylated by PKA. Activation
of cGKII by cGMP increases the surface expres-
sion of AMPARs at extrasynaptic sites. Inhibi-
tion of cGKII activity blocks the surface in-
crease of GluR1 during chemLTP and reduces
LTP in the hippocampal slice. This work iden-
tifies a pathway, downstream from the NMDA
receptor (NMDAR) and nitric oxide (NO), which
stimulates GluR1 accumulation in the plasma
membrane and plays an important role in syn-
aptic plasticity.
INTRODUCTION
AMPARs are ionotropic glutamate receptors that mediate
rapid excitatory transmission in the mammalian brain.
They are heterotetrameric cation channels comprised of
a combinatorial assembly of four subunits, GluR1-GluR4
(GluRA-D) (Hollmann and Heinemann, 1994). Regulated
trafficking of AMPARs has emerged as an important
mechanism that underlies the activity-dependent modifi-
cation of synaptic strength. Delivery of AMPARs to the
postsynaptic membrane leads to long-term potentiation
(LTP), whereas removal of these receptors leads to long-
term depression (LTD) (Barry and Ziff, 2002; Bredt and
Nicoll, 2003; Malinow and Malenka, 2002; Sheng and
Lee, 2001; Song and Huganir, 2002). Both of these forms670 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inof synaptic plasticity are influenced by NMDAR activity
(Bliss and Collingridge, 1993; Malenka and Bear, 2004).
Regulation of AMPAR synaptic insertion is determined
by the receptor subunit composition. While synaptic activ-
ity drives GluR1-containing receptors to the synapse, thus
enhancing transmission, AMPARs lacking GluR1, such as
GluR2/3 heteromers, constitutively cycle in and out of the
synapse, in an activity-independent manner, entering and
leaving sites initially occupied by GluR1-containing recep-
tors. This distinction in subunit trafficking is determined by
the subunit intracellular CTDs (Passafaro et al., 2001; Shi
et al., 2001).
Several lines of evidence indicate that GluR1 has an
important role in LTP. GluR1 is delivered to the synapse
during LTP (Hayashi et al., 2000), adult GluR1/ mice
do not express LTP in CA3 to CA1 synapses (Zamanillo
et al., 1999), and LTP is deficient in mice with knockin
mutations in the GluR1 PKA and CaMKII phosphorylation
sites (Lee et al., 2003). The molecular mechanisms that
regulate GluR1 synaptic delivery during LTP are complex
and involve interactions of the GluR1 CTDwith scaffolding
proteins, such as protein 4.1N and SAP97 (Leonard et al.,
1998; Shen et al., 2000), and a series of phosphorylation
steps at several Ser residues on the GluR1 CTD (Boehm
and Malinow, 2005). The CTD of GluR1 is phosphorylated
at S831 by both CaMKII and PKC (Barria et al., 1997;
Mammen et al., 1997; Roche et al., 1996), at S845 by
PKA (Roche et al., 1996), and at S818 by PKC (Boehm
et al., 2006). While CaMKII drives GluR1 to the synapse
and may contribute to induction of LTP, a mutation of
GluR1 S831 that prevents phosphorylation by CaMKII
does not prevent synaptic delivery of the receptor by
active CaMKII or LTP (Hayashi et al., 2000), suggesting
that CaMKII acts on a different target to induce GluR1
synaptic delivery. Interestingly, mutagenesis of S845 of
GluR1 showed that phosphorylation of this site is re-
quired, although not sufficient, for GluR1 synaptic inser-
tion during LTP (Esteban et al., 2003). Phosphorylation
of S845 by PKA has also been shown to increase the de-
livery of AMPARs to extrasynaptic sites and to prime the
receptor for synaptic insertion (Oh et al., 2006; Sun
et al., 2005).c.
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cGKII Regulates GluR1 TraffickingMany studies have suggested that the diffusible second
messenger, nitric oxide (NO), contributes to the mecha-
nism of LTP (Bon et al., 1992; Bon and Garthwaite,
2003; Haley et al., 1992; O’Dell et al., 1994; Schuman
and Madison, 1991; Zhuo et al., 1993), and LTP in the
CA1 region of hippocampus is reduced in double-
knockout mice lacking both endothelial and neuronal NO
synthase (eNOS and nNOS, respectively) (Son et al.,
1996), the two major NO-producing enzymes in the brain.
Although many studies have addressed the role of NO in
LTP, the molecular mechanisms underlying the NO regu-
lation of synaptic plasticity are still elusive. NO activates
soluble guanylate cyclase (sGC), which induces the for-
mation of cGMP, and one cGMP target is the cGMP-
dependent kinases (cGKs). There are two cGK isoforms,
cGKI and cGKII. While cGKI is cytosolic and in the brain
is preferentially enriched in the cerebellum, cGKII is lo-
cated in cellular membranes and is widely distributed in
the brain (Francis and Corbin, 1999).
Here we report that cGKII binds the GluR1 CTD in
a cGMP-dependent manner and that in this complex
cGKII can phosphorylate S845 of GluR1 and increase
GluR1 levels in the plasma membrane. Glycine-induced
chemLTP promotes cGKII interaction with GluR1 and
phosphorylation of S845. Expression of a cGKII inhibitor
peptide in cultured hippocampal neurons blocks the in-
crease of surface GluR1 and of mEPSCs frequency and
amplitude after chemLTP, and when expressed in the
mouse hippocampus, reduces LTP in the hippocampal
slice. This function of cGKII provides a mechanism for in-
creasing the levels of GluR1 in the plasma membrane that
complements the PKA-induced GluR1 surface increase.
Because the NMDAR regulates NO production by nNOS,
and hence controls cGMP levels and cGKII activity, this
pathway provides a mechanism for NMDAR and NO con-
trol of GluR1 accumulation in the plasma membrane.
RESULTS
Interaction of the GluR1 CTD with cGKII
Using the GluR1 CTD as bait, we screened 23 106 cDNAs
for GluR1 CTD interactors by the Sos recruitment system,
which detects protein-protein interactions in the yeast
cytoplasm (Aronheim et al., 1997). We obtained three in-
dependent positive transformants, which all encoded the
region between aa 400–762 of cGKII. cGKII is comprised
of three functional domains, an N-terminal regulatory
domain, a cGMP-binding domain that contains two tan-
dem cGMP-binding sites, and a catalytic domain (Pfeifer
et al., 1999) (Figure 1B). The N-terminal domain contains
a dimerization domain and an autoinhibitory (AI) domain,
which includes autophosphorylation sites. The clones
encoded the second cGMP-binding domain plus the cat-
alytic domain, located at the cGKII C terminus (Figure 1B).
In the Sos recruitment assay, neither deletion of the last 8
aa of GluR1, which contain the PDZ ligand and is required
for interaction with SAP97 (Leonard et al., 1998) (Fig-Neuure 1Ai), nor deletion of the region from the membrane-
spanning domain to aa 839, a region required for protein
4.1N interaction (Shen et al., 2000) (Figure 1Ai), blocked
the aa 400–762 cGKII interaction (Figure 1Aii). We con-
clude that aa 839–881 of the GluR1 CTD, a region not
known to bind other proteins, is important for the interac-
tion with cGKII.
Using a mammalian recruitment system in 293T cells,
we confirmed that the GluR1 CTD fused to GFP
(GluR1C-GFP) bound the plasma membrane-anchored
cGKII catalytic domain (cGKII aa 400–762) (see Figure S1
in the Supplemental Data available with this article online)
and found that the C-terminal 173 aa of cGKII, which
contain a segment of the catalytic domain, are required
for interaction with GluR1 (Figure S1 and Figure 1B).
Regulation ofGluR1CTDBinding to cGKII by cGMP
In the cGKII inactive, autoinhibited state, the cGKII AI
domain binds the substrate-docking domain at the cata-
lytic site (Figure 1B). Activation by cGMP unfolds the AI
domain and exposes the C-terminal catalytic domain
(Wall et al., 2003; Zhao et al., 1997). We speculated that
in the full-length cGKII, the AI domain-catalytic domain
interaction could block GluR1 binding to the catalytic
domain. If so, displacement of the AI following cGMP ac-
tivation of cGKII could facilitate GluR1 interaction with the
full-length kinase. In a GST pulldown assay, the GluR1
CTD fused to GST (GST-GluR1C) pulled down full-length
cGKII from lysates of both control and 8-Br-cGMP-treated
293T cells expressing full-length cGKII (Figure 1C). How-
ever, strikingly, treatment of 293T cells with 8-Br-cGMP
greatly increased the interaction with cGKII (Figure 1C).
As controls, neither GST alone nor the GluR2 CTD fused
to GST (GST-GluR2C) pulled down cGKII, even after
8-Br-cGMP treatment (Figure 1D). These results confirm
that the GluR1 CTD interacts with full-length cGKII and
that kinase activation increases the interaction.
We used GST GluR1 CTD deletion mutant pulldowns to
map the cGKII-interacting region within the CTD (Figure
1E and Figure S2). While certain CTD mutants bound
cGKII with intermediate affinity (Figure S2), the GluR1
CTD 23 aa sequence between aa 850 and aa 873was nec-
essary and sufficient for binding cGKII, although binding
was decreased compared toWT (Figure 1E). The CTDmu-
tation R837A also decreased CTD binding to cGKII, and
the mutation R837E completely disrupted the binding
(Figure 1E), suggesting that R837 is critical for the cGKII-
GluR1 interaction.
cGKII Cofractionates and Colocalizes with GluR1
and Binds GluR1 In Vivo
Myristoylation of the Gly2 residue targets cGKII to the
plasma membrane (Vaandrager et al., 1996). In assays
of the cGKII brain subcellular distribution, cGKII was pres-
ent in the synaptosome and postsynaptic density (PSD)
fractions but was most abundant in the lipid raft fraction
of the synaptosomes (Figure 2A). GluR1 was also in the
lipid raft fraction (Figure 2A), as previously shown (Heringron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 671
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cGKII Regulates GluR1 TraffickingFigure 1. Interaction between cGKII and GluR1
(A) Yeast two-hybrid analysis of the GluR1 CTD and the cGKII catalytic domain interaction. (Ai) Schematic of the GluR1 CTD and the regions required
for binding with protein 4.1N and SAP97. (Aii) The GluR1 CTD and deletion mutants were screened for interaction with the aa 400–762 fragment of
cGKII (cGKII aa 400–762) by the Sos recruitment system as described in Experimental Procedures.
(B) Schematic of cGKII fragments and interaction with the GluR1 CTD in the mammalian recruitment assay (see Figure S1).
(C) Interaction of the GluR1 CTD with full-length cGKII, and stimulation by cGMP. Lysates of 293T cells expressing WT cGKII were incubated with
GST-GluR1C. 293T cells were either treated with 8-Br-cGMP (50 mM) for 10 min or left untreated (control) before lysis. The supernatant (SN) and
the pellet (P) fractions were fractionated by SDS PAGE. The P fraction contains bound proteins, and the SN contains unbound proteins. The whole
P and approximately 10% of the SN were fractionated in the gel. Proteins were detected by IB. Bottom panel shows the Coomassie blue staining of
GST species and their degradation products, which are commonly seen.
(D) Specificity of the GluR1 CTD and cGKII interaction. Lysates from 293T cells expressing WT cGKII were incubated with GST, GST-GluR1C, and
GST-GluR2C. 293T cells were treated with 8-Br-cGMP (50 mM) for 10 min before lysis. Bound proteins were detected by IB. Bottom panel shows the
Coomassie blue staining of GST species.
(E) GST pulldown experiment. Lysates from 293T cells expressing cGKII were incubated with GST alone or with GST-GluR1C deletion mutants. 293T
cells were treated with 8-Br-cGMP (50 mM) for 10 min before lysis. Bound proteins were detected by IB. A 23 aa region between aa 850 and aa 873 in
the GluR1 CTD is necessary and sufficient for binding with cGKII.et al., 2003), and thus in the same cellular compartment as
cGKII.
In cultured hippocampal neurons, cGKII was punctate
in the somatic cytoplasm and in neurites (Figure 2B). cGKII
puncta colocalized with or were adjacent to synaptophy-
sin puncta, suggesting a synaptic location. GluR1 also dis-
played puncta that in many cases colocalized with the
cGKII puncta (Figure 2C), confirming GluR1 and cGKII672 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inpresence in the same cellular compartment. Furthermore,
an antiserum to cGKII, but not a control IgG, coprecipi-
tated GluR1 with cGKII from brain synaptosomal lysate
(Figure 2D), confirming the cGKII-GluR1 interaction in
the brain synaptosomal compartment, which is a synaptic
and perisynaptic fraction. Significantly, treatment of cul-
tured neurons with 8-Br-cGMP (500 mM; 5 min) increased
the coprecipitation of GluR1 with cGKII, confirming thatc.
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cGKII Regulates GluR1 TraffickingFigure 2. cGKII Interacts with GluR1 in the Brain and in Cortical Cultures, Colocalizes with GluR1 in Cultured Hippocampal
Neurons, and Phosphorylates GluR1 S845 In Vitro and In Vivo
(A) Subcellular fractionation of adult rat brains. Equal amounts of rat brain fractions were analyzed by IB and probed as indicated. P2, crude mem-
branes; PSD, postsynaptic density.
(B) Hippocampal neuron stained for endogenous MAP2 (blue), cGKII (red), and synaptophysin (green). Scale bar, 20 mm. Arrows indicate cGKII and
synaptophysin colocalization.
(C) Endogenous cGKII (green) and GluR1 (red) staining in hippocampal neurons. Scale bar, 5 mm. Arrows indicate cGKII and GluR1 colocalization.
(D) cGKII associates with GluR1 in rat brain tissue. Rat brain synaptosomal lysates were precipitated with a control IgG, an anti-cGKII Ab, or an anti-
GluR1 Ab. Bound proteins were detected by IB.
(E) 8-Br-cGMP increases the interaction of cGKII with GluR1 in cortical cultures. Cells were treated with 8-Br-cGMP or saline (control). Cellular lysates
were precipitated with an anti-cGKII Ab, and bound proteins were detected by IB.
(F) CoIP performed as in (E). Glycine and the NO donor NOR-3 increase the interaction of GluR1 with cGKII.
(G) In vitro phosphorylation of the GluR1 CTD by cGKII. GST, GST-GluR1C, and GST-GluR2C were incubated with the indicated purified kinases
and [g-32P] ATP, resolved by SDS-PAGE, and analyzed by autoradiography. (Gi) Phosphorylation of GST-GluR1C by cGKII. The arrows indicate
autophosphorylated cGKII. The lower cGKII band is a degradation product of the purified cGKII used in these assays. (Gii) Phosphorylation of
GST-GluR1C by PKA.
(H) PhosphorylatedGST-GluR1Cpulls down autophosphorylated cGKII. (Hi) GST-GluR1Cwas incubatedwith purified cGKII in the presence of [g-32P]
ATP. After incubation, protein complexes containing GST-R1Cwere analyzed by pulldown and autoradiography. The arrows indicate autophosphory-
lated cGKII. The lower cGKII band is a degradation product of the purified cGKII used in these assays. (Hii) Same as in (Hi), but the reaction was in-
cubatedwith unlabeled ATP. Proteinswere detected by IB. The same two bands seenwith labeled ATP in (Hi) were seen after IB with an anti-cGKII Ab.
(I) In vitro phosphorylation of GST-GluR1C at S845 by cGKII and PKA. Reactions were performed as in (A), but with unlabeled ATP. Levels of S845-PO4
and of total GluR1C were determined by SDS-PAGE and IB using phosphospecific and total GluR1 Abs, respectively.
(J) GluR1 phosphorylation at S845 in cortical cultures is increased by stimulation of the NMDA-NO-cGKII pathway. Cortical cultures were treated with
glycine, theNOdonorNOR-3,8-Br-cGMP,orwith saline (control). Inhibitorsusedas indicatedwereAP5,NMDARantagonist, andKT5823, cGK inhibitor.
Cultureswerepreincubated for30minwithokadaicacid (1mM) to inhibitphosphataseactivity.Total amountofGluR1wasassayedwithananti-GluR1Ab.
(K)Quantitationof thecGKII phosphorylationofGluR1S845 fromseveral experimentsas the oneshown in (D). Phosphospecific signalwasnormalized to
the total amount of GluR1, and final values were normalized to control. *p < 0.05, n = 4.Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 673
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cGKII Regulates GluR1 TraffickingFigure 3. Effects of cGKII Activation on GluR1 Trafficking
(Ai) Hippocampal neurons expressing HAGluR1 and treated for 5 min with saline (control), 8-Br-cGMP, or 8-Br-cGMP following pretreatment with the
cGK inhibitor KT5823. Neurons were stained live for surface HA (red), followed by fixation, permeabilization, and staining for total HA (green). Scale
bar, 20 mm. (Aii) Quantitation of surface/total ratio of HAGluR1 on neurons from experiments as the one shown in (Ai). Bar graph shows mean ± SEM;
n = 35 for control, 30 for 8-Br-cGMP, and 20 for 8-Br-cGMP + KT5823; **p < 0.01.
(Bi) Representative images of hippocampal neurons expressing HAGluR1 or HAGluR1-S845A and treated for 5 min with saline (control) or 8-Br-
cGMP. Staining was done as in (Ai). Scale bar, 20 mm. (Bii) Quantitation of surface/total ratio of HAGluR1 and HAGluR1-S845A on neurons from
experiments as the one shown in (Bi). Bar graph shows mean ± SEM; n = 33 for HAGluR1 WT, 20 for HAGluR1-S845A, and 20 for HAGluR1-
S845A + 8-Br-cGMP; NS = nonsignificant.
(C) Quantitation of surface/total ratio of HAGluR1 WT and HAGluR1-S845A on neurons treated for 10 min with saline (control) or NOR-3. Bar graph
shows mean ± SEM; n = 20 for HAGluR1 WT control, 18 for HAGluR1 WT + NOR-3, 22 for HAGluR1-S845A control, and 24 for HAGluR1-S845A +
NOR-3; **p < 0.01.
(D) Images of surface GluR1 (red) and SV2 (green) staining in hippocampal neurons treated with saline (control), glycine for chemLTP, 8-Br-cAMP, or
8-Br-cGMP. Neurons were stained live for surface GluR1, and after fixation and permeabilization, for SV2. Scale bar, 2 mm.674 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc.
Neuron
cGKII Regulates GluR1 TraffickingcGMP increases their binding (Figure 2E). In a chemical
form of LTP (chemLTP), short application of glycine at
high concentration selectively activates synaptic NMDA
receptors (Lu et al., 2001). Ca2+ influx through the NMDAR
activates nNOS, which increases NO, which activates the
cGMP-producing enzyme sGC (Bredt and Snyder, 1989;
Garthwaite et al., 1988). Glycine application (200 mM;
3 min) increased the interaction of cGKII with GluR1, as
did the NO donor, NOR-3 (10 mM; 10 min) (Figure 2F).
This confirms that NMDAR activation, NO, or cGMP all
can increase the interaction of GluR1 with cGKII.
cGKII Phosphorylates GluR1 at S845 In Vitro
and In Vivo
GluR1 CTD S818, S831, and S845 are major phosphory-
lation sites (Boehm et al., 2006; Roche et al., 1996).
When incubated with GST-GluR1C and [g-32P] ATP,
purified cGKII robustly phosphorylated GST-GluR1C
(Figure 2Gi). This was specific since cGKII phosphory-
lated neither GST alone nor GST-GluR2C (Figure 2Gi).
As expected, PKA also phosphorylated GST-GluR1C
(Figure 2Gii).
We next tested whether autophosphorylated cGKII
could physically interact with GST-GluR1C as well as
phosphorylate it (Figure 2H). When we incubated GST-
GluR1C and cGKII with [g-32P] ATP, 32P-labeled cGKII
was pulled down by GST-GluR1C, which was also 32P
labeled. Thus, cGKII not only phosphorylates GluR1, but
activated autophosphorylated cGKII can physically inter-
act with the phosphorylated GluR1 CTD (Figure 2H).
Among the protein kinases, cGKs (cGKI and cGKII) are
most closely related to PKA, and cGKs frequently recog-
nize the canonical PKA phosphorylation site motif (Wang
and Robinson, 1997). Also, both kinase types share
substrates in the brain, with DARPP-32 being one exam-
ple (Hemmings et al., 1984). Since PKA phosphorylates
S845 of GluR1, we assayed cGKII phosphorylation of
this site. Notably, incubation of GST-GluR1C with either
cGKII or PKA increased the signal for S845-PO4 detected
by immunoblotting (IB) with a phosphopeptide-specific Ab
to S845-PO4 (Figure 2I). Thus, in vitro, cGKII phosphory-
lates GluR1 at S845. Furthermore, in cultured neurons,
glycine, the NO donor NOR-3, and 8-Br-cGMP all in-
creased S845 phosphorylation (Figures 2J and 2K). Pre-
treating with the NMDAR blocker, AP5 (25 mM; 20 min),
or with the cGKII inhibitor, KT5823 (2 mM; 30 min), before
glycine application, abolished the increase of S845 phos-
phorylation, confirming that glycine acts through the
NMDAR and requires cGKII activity (Figures 2J and 2K).
However, AP5 pretreament did not prevent the effects ofNeuNOR-3 on S845 phosphorylation, although KT5823 re-
duced the increase of S845 phosphorylation after NOR-
3 treatment almost to control levels (Figures 2J and 2K).
We conclude that cGKII phosphorylates GluR1 at S845
in vitro and that activation of cGKII, which is under the
regulation of the NMDAR and NO, leads to S845 phos-
phorylation in neurons.
cGKII Activation Increases Surface GluR1
Phosphorylation of S845 by PKA is sufficient to increase
GluR1 at the plasma membrane (Oh et al., 2006). When
we expressed epitope-tagged GluR1 (HAGluR1) from a
viral vector in cultured hippocampal neurons (Figure 3A),
a 5 min 8-Br-cGMP (500 mM) treatment caused a signifi-
cant increase in the surface/total ratio of HAGluR1, com-
pared to control cells (control: 1 ± 0.14; 8-Br-cGMP:
2.18 ± 0.26; values normalized to control, p < 0.01)
(Figures 3Ai and 3Aii) that was significantly blocked by
preincubation with KT5823 (2 mM, 30 min) (1.26 ± 0.22)
(Figures 3Ai and 3Aii), suggesting that cGKII mediates
a cGMP-dependent accumulation of GluR1 at the plasma
membrane (Figure 3A). In contrast, surface/total ratio of
HAGluR1-S845A, which cannot be phosphorylated at
S845, was not significantly increased by 8-Br-cGMP com-
pared to untreated HAGluR1-S845A (untreated HAGluR1-
S845A: 0.72 ± 0.11, HAGluR1-S845A+ 8-Br-cGMP: 0.99 ±
0.07; p > 0.05) or to untreated WT (1 ± 0.09, p > 0.05)
(Figures 3Bi and 3Bii). Similar results were obtained
when neurons were infected with WT HA-GluR1 or
HAGluR1-S845A and treated with the NO donor NOR-3
(10 mM, 10 min) (HAGluR1 WT + saline [control]: 1 ± 0.1,
HAGluR1 WT + NOR-3: 4.6 ± 0.9, p < 0.005; and
HAGluR1-S845A + saline [control]: 1 ± 0.1, HAGluR1-
S845A + NOR-3: 0.9 ± 0.1, p > 0.05) (Figure 3C). These
results indicate that phosphorylation of S845 is required
for the cGMP- and the NO-dependent GluR1 surface
increase.
PKA increases surface GluR1 but only at extrasynaptic
sites (Oh et al., 2006; Sun et al., 2005). To determine
whether cGKII acted similarly, we assayed GluR1 surface
location following 8-Br-cGMP application, with chemLTP,
which increases GluR1 synaptic insertion (Lu et al., 2001),
as a control (Figure 3D). We measured synaptic GluR1 by
quantifying, through immune fluorescence labeling, the
intensity of the GluR1 fluorescent signal that overlaps
with the signal of SV2, a synaptic marker, divided by the
total intensity of the GluR1 signal (see Experimental Pro-
cedures). In control conditions, 34% ± 2% of surface
GluR1 overlapped with the synaptic marker SV2 (Figures
3D and 3F). Although both 8-Br-cAMP (500 mM) and(E) Quantitation of surface levels of GluR1 on neurons from experiments as the one shown in (D). Bar graph showsmean ± SEM; n = 18 for control, 15
for glycine, 16 for 8-Br-cAMP, and 19 for 8-Br-cGMP; ***p < 0.001.
(F) Quantitation of synaptic GluR1 on neurons from experiments similar to those of (D). Synaptic GluR1 was expressed as the intensity of the GluR1
signal that overlapped with SV2 divided by the total intensity of the GluR1 signal. Bar graph shows mean ± SEM; n = same as in (B); ***p < 0.001.
(G) Examples of mEPSCs before (5 min) and 5 and 25 min after the application of glycine.
(H) Application of glycine (n = 6, filled red circles), but neither 8-Br-cGMP (n = 6, open green squares) nor 8-Br-cAMP (n = 6, open black squares)
enhanced mEPSC amplitude in cultured hippocampal neurons. Controls were performed with vehicle (n = 5, open red circles). The thick line repre-
sents the duration of glycine, 8-Br-cGMP, or 8-Br-cAMP application, and error bars represent SEM.ron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 675
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cGKII Regulates GluR1 TraffickingFigure 4. Trafficking of GluR1 by cGMP and cAMP
(Ai) Images of surface GluR1 in neurons treated for 5 min with saline (control), 8-Br-cGMP, 8-Br-cGMP following pretreatment with the PKA inhibitor
KT5720, or 8-Br-cGMP following pretreatment with the cGK inhibitor KT5823. Neurons were then stained live for surface GluR1. Scale bar, 2 mm. (Aii)
Quantitation of surface levels of GluR1 on neurons from experiments as the ones shown in (Ai). Bar graph shows mean ± SEM; n = 20 for all exper-
imental groups; *p < 0.05, ***p < 0.001.
(Bi) Images of surface GluR1 in neurons treated for 5 min with saline (control), 8-Br-cAMP, 8-Br-cAMP following pretreatment with the cGK inhibitor
KT5823, or 8-Br-cAMP following pretreatment with the PKA inhibitor KT5720. Staining was done as in (A). Scale bar, 2 mm. (Bii) Quantitation of surface
levels of GluR1 on neurons from experiments as the ones shown in (Bi). Bar graph showsmean ± SEM; n = 20 for control, 14 for 8-Br-cAMP, and 16 for
8-Br-cAMP + KT2823 and 8-Br-cAMP + KT5720; **p < 0.005, ***p < 0.001.
(Ci) Images of surface GluR1 (red) in neurons treated for 5 min with saline (control), 8-Br-cAMP, or 8-Br-cAMP following pretreatment with the cGKII
inhibitor Rp-8-pCPT-cGMPS. Neurons were then stained live for surface GluR1, followed by fixation, permeabilization, and staining for MAP2 (green).
Scale bar, 2 mm. (Cii) Quantitation of surface levels of GluR1 on neurons from experiments as the one shown in (Ci). Bar graph shows mean ± SEM;
n = 30 for control, 30 for 8-Br-cAMP, and 27 for 8-Br-cAMP + Rp-8-pCPT-cGMPS. ***p < 0.001.676 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc.
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cGKII Regulates GluR1 Trafficking8-Br-cGMP increased surface GluR1 (Figures 3D and 3E),
neither treatment significantly changed the amount of syn-
aptic GluR1, measured as the overlap with SV2 (40% ±
2% of GluR1 overlapped with SV2 in cells treated with
8-Br-cAMP, p > 0.05, compared to control, and 39% ±
2% in cells treated with 8-Br-cGMP, p > 0.05, compared
to control) (Figure 3F). Induction of chemLTP by glycine in-
creased surface GluR1 relative to the control (control: 1 ±
0.15, glycine: 2.7 ± 0.44, p < 0.001) (Figure 3E). However,
as opposed to 8-Br-cAMP and 8-Br-cGMP treatment,
chemLTP also significantly increased the overlap of GluR1
with SV2 relative to control (70% ± 3%, p < 0.001), as
expected (Figures 3D and 3F). These results suggest
that while glycine, cGMP, and cAMP all increase GluR1
surface levels, only with chemLTP is synaptic GluR1
increased.
To validate these results using electrophysiology, we
recorded miniature excitatory postsynaptic currents
(mEPSCs) on the cultured hippocampal neurons (Fig-
ure 3G). Consistent with the earlier study (Lu et al.,
2001), application of glycine (200 mM, 3 min) produced
an immediate and long-lasting increase in mEPSC ampli-
tude (131.6% ± 12.3% of baseline at 25 min after glycine
application, n = 6) (Figures 3G and 3H). However, unlike
glycine, neither 8-Br-cGMP (500 mM) nor 8-Br-cAMP
(500 mM) enhanced mEPSC amplitude (93.3% ± 16.3%
of baseline at 25 min after 8-Br-cGMP application, n = 6;
78.6% ± 10.1% of baseline at 25 min after 8-Br-cAMP
application, n = 6) (Figure 3H), confirming that while
8-Br-cGMP or 8-Br-cAMP increase surface GluR1 (Fig-
ure 3D), they are not sufficient to induce GluR1 synaptic
insertion (Figure 3H).
cGKII Action Is Independent from PKA
Our results suggest that cGKII and PKA share a common
mechanism to increase GluR1 in the plasma membrane.
To rule out the possibility of cross-talk between the cyclic
nucleotide pathways, in which cGMP activates PKA or
cAMP activates cGKII, we tested the effects of pharmaco-
logical inhibitors specific for cGKII and PKA (Figure 4).
8-Br-cGMP increased the surface level of endogenous
GluR1 approximately 3.5-fold (value of 3.48 ± 0.30,
treated cells; 1 ± 0.15, control; p < 0.001) (Figures 4Ai
and 4Aii). The effects of 8-Br-cGMP were reduced almost
to control levels by the cGKII-specific inhibitor KT5823
(GluR1 surface level of 1.60 ± 0.21), but not by the PKA
inhibitor KT5720 (2 mM, 30 min) (3.47 ± 0.51, p < 0.001),
(Figures 4Ai and 4Aii). Similarly, the increase in surface
AMPARs by 8-Br-cAMP (2.82 ± 0.38; control values
same as above; p < 0.001) was inhibited by the PKA inhib-
itor KT5720 (1.32 ± 0.24; p > 0.05, compared to control)
(Figures 4Bi and 4Bii), while the cGKII inhibitor KT5823,
although it slightly reduced the cAMP-dependent increaseNeuof surface GluR1, still left significantly higher levels of
surface receptors compared to the control (1.94 ± 0.22;
p < 0.01) (Figures 4Bi and 4Bii).
We confirmed these results with Rp-8-pCPT-cGMPS,
a more potent and very highly cell-permeable cGKII inhib-
itor (Butt et al., 1994), which blocks nucleotide binding to
the cGMP-binding site of cGKII, while KT5823 inhibits ATP
binding to the catalytic domain (Kase et al., 1987). Rp-8-
pCPT-cGMPS (10 mM, 30 min) did not reduce surface
GluR1 following 8-Br-cAMP application (1 ± 0.13, control;
3.18 ± 0.2, 8-Br-cAMP; 3.23 ± 0.25, 8-Br-cAMP + Rp-8-
pCPT-cGMPS) (Figures 4Ci and 4Cii); however, it com-
pletely prevented the 8-Br-cGMP increase of surface
GluR1 (1 ± 0.08, control; 2.72 ± 0.21, 8-Br-cGMP; 0.97 ±
0.11, 8-Br-cGMP + Rp-8-pCPT-cGMPS) (Figures 4Di
and 4Dii). We conclude that 8-Br-cGMP acts through
cGKII, that its effects are independent from PKA, and
that each kinase can act independently to increase the
levels of GluR1 in the plasma membrane.
Different Molecular Mechanisms Mediate GluR1
Phosphorylation by PKA and cGKII
The GluR1 carboxyl terminus binds SAP97, a PDZ scaf-
folding protein that binds the A kinase anchoring protein,
AKAP79, which binds and tethers PKA (Colledge and
Scott, 1999). Phosphorylation of GluR1 by PKA requires
this complex, since disruption of the SAP97-GluR1 inter-
action decreased PKA phosphorylation of S845 (Colledge
et al., 2000). Because cGKII directly binds GluR1, we
hypothesized that its structural requirements for phos-
phorylation of GluR1 will differ. Both 8-Br-cAMP and
8-Br-cGMP significantly increased the phosphorylation
of HAGluR1WT in neuronal cultures, as expected (Figures
5Ai and 5Aii). However, 8-Br-cAMP did not increase S845
phosphorylation of HAGluR1D7, a mutant that lacks the
last 7 amino acids of GluR1 and does not bind the
SAP97-AKAP-PKA complex, although 8-Br-cGMP still in-
duced a significant increase of HAGluR1D7 S845 phos-
phorylation (Figures 5Bi and 5Bii). Thus, cGKII does not
require the GluR1 PDZ ligand. Likewise, while 8-Br-
cAMP did not change the surface/total ratio of HAGluR1-
D7 (ratio of 1 ± 0.1 for untreated HAGluR1D7 and 1.1 ± 0.1
for HAGluR1D7 + 8-Br-cAMP, p > 0.05), 8-Br-cGMP did
increase the HAGluR1D7 surface/total ratio significantly
(1.43 ± 0.1, p < 0.001, compared to untreated) (Figure 5C).
Thus, PKA but not cGKII requires the GluR1 PDZ ligand to
regulate GluR1 trafficking, as expected from the structural
interactions. Moreover, in the absence of PKA regulation
of GluR1, cGKII regulation of GluR1 is not significantly
affected.
We next tested the structural requirements for cGKII ac-
tion. Our mutagenesis study showed that R837 mutation
to Ala reduced the interaction with cGKII, while mutation(Di) Images of surface GluR1 (red) in neurons treated for 5 min with saline (control), 8-Br-cGMP, or 8-Br-cGMP following pretreatment with the cGKII
inhibitor Rp-8-pCPT-cGMPS. Neurons were then stained live for surface GluR1, followed by fixation, permeabilization, and staining for MAP2 (green).
Scale bar, 2 mm. (Dii) Quantitation of surface levels of GluR1 on neurons from experiments as the one shown in (Di). Bar graph shows mean ± SEM;
n = 29 for control, 27 for 8-Br-cGMP, and 26 for 8-Br-cGMP + Rp-8-pCPT-cGMPS. ***p < 0.001.ron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 677
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cGKII Regulates GluR1 TraffickingFigure 5. Different Molecular Mechanisms Mediate Phosphorylation and Trafficking of GluR1 by PKA and cGKII
(Ai) Lysates from neurons infected with HAGluR1 WT were precipitated with an anti-HA Ab. The IPs were probed with the indicated Abs. NTD = N
terminal domain. (Aii) Quantitation of S845 phosphorylation from several experiments as the one shown in (Ai). Phosphospecific signal was normalized
to the total amount of GluR1, and final values were normalized to control. ***p < 0.001, n = 3.
(Bi) Lysates from neurons infected with HAGluR1D7 were precipitated with an anti-HA Ab. The IPs were probed with the indicated Abs. Note that
HAGluR1D7 is not recognized by the GluR1 CTD Ab, since this Ab recognizes a sequence present in the C terminus of GluR1, which has been deleted
in HAGluR1D7 (see text). (Bii) Quantitation of S845 phosphorylation from several experiments as the one shown in (Bi). Phosphospecific signal was
normalized to the total amount of GluR1, and final values were normalized to control. ***p < 0.001, n = 3.
(C) Hippocampal neurons expressing HAGluR1D7 and treated for 5min with saline (control), 8-Br-cAMP, or 8-Br-cGMP. Neuronswere stained live for
surface HA (red), followed by fixation, permeabilization, and staining for total HA (green). Scale bar, 20 mm; lower panel, 2 mm. The right lower panel
shows the quantitation of surface/total ratio of HAGluR1. Bar graph showsmean ± SEM; n = 35 for control, 30 for 8-Br-cAMP, and 20 for 8-Br-cGMP+
KT5823; ***p < 0.001.
(Di) In vitro phosphorylation of GST-GluR1C WT, GST-GluR1C R837A, and GST-GluR1C R837E at S845 by cGKII. Levels of S845-PO4 and of total
GluR1C were determined by SDS-PAGE and IB using phosphospecific and total GluR1 Abs, respectively. (Dii) Quantitation of S845 phosphorylation
from several experiments as the one shown in (Di). Phosphospecific signal was normalized to the total amount of GluR1, and final values were
normalized to control. *p < 0.05, **p < 0.005, n = 3.
(E) Hippocampal neurons expressing HAGluR1 WT, HAGluR1 R837A, and HAGluR1 R837E. Neurons were stained live for surface HA (red), followed
by fixation, permeabilization, and staining for total HA (green). Scale bar, 20 mm; lower panel, 2 mm.678 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc.
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cGKII Regulates GluR1 Traffickingto Glu completely disrupted the interaction (Figure 1E). In
the in vitro S845 phosphorylation of GST-GluR1C by
cGKII, the level of S845 phosphorylation of GST-GluR1C
R837A was reduced, and phosphorylation of GST-
GluR1C R837E was further reduced, when compared to
WT (Figures 5Di and 5Dii). Thus, the phosphorylations of
these mutants directly correlated with their degrees of
binding to cGKII (Figures 5Di and 5Dii, compare with
Figure 1E). This shows that interaction of cGKII with
GluR1 promotes phosphorylation of the receptor.
We next tested directly the role of the cGKII-GluR1 in-
teraction in the increase of GluR1 surface levels (Fig-
ure 5E). Surface/total ratio was reduced approximately
40% for HAGluR1 R837A, relative to WT (ratio of 1 ± 0.1
in WT and 0.59 ± 0.07 in HAGluR1 R837A, p < 0.005),
and was even more greatly reduced for HAGluR1 R837E
(0.35 ± 0.05, p < 0.001 compared to WT) (Figures 5E
and 5F). Thus, disrupting the cGKII-GluR1 interaction
affects GluR1 surface accumulation. Moreover, 8-Br-
cGMP increased HAGluR1 R837A surface levels only
slightly (ratio of 1.29 ± 0.12 for HAGluR1 R837A + 8-Br-
cGMP and 1 ± 0.1 for untreated HAGluR1 R837A, p >
0.05) (Figure 5G), and strikingly, 8-Br-cGMP did not
increase HAGluR1 R837E surface levels (1.07 ± 0.11 for
HAGluR1 R837E + 8-Br-cGMP and 1.0 ± 0.08 for un-
treated HAGluR1 R837E, p > 0.05) (Figure 5H), showing
that interaction of cGKII with GluR1 is necessary for the
cGMP-dependent increase of surface GluR1. Contrary
to 8-Br-cGMP, 8-Br-cAMP still increased surface levels
of HAGluR1 R837A (1.54 ± 0.11, p < 0.001, compared to
untreated HAGluR1 R837A) (Figure 5G) and HAGluR1
R837E (1.42 ± 0.11, p < 0.001, compared to untreated
HAGluR1R837E) (Figure 5H). Thus, progressively destabi-
lizing the cGKII-GluR1 interaction results in a progressive
decrease of the constitutive levels of surface GluR1 and
progressively impairs GluR1 responsiveness to cGMP.
Moreover, these results establish that different molecular
mechanisms underlie GluR1 phosphorylation and surface
increase by PKA and cGKII.
cGKII Mediates a Critical Step in GluR1 Trafficking
and Synaptic Plasticity
We next examined the pathway downstream from the
NMDAR, specifically whether the NMDAR requires activa-
tion of cGKII via nNOS and sGC to increase AMPARs in
the plasma membrane. During chemLTP, the glycine-
induced surface increase of GluR1 was blocked by AP5
(25 mM), by nNOS inhibitor I (10 mM), by the sGC inhibitor
ODQ (10 mM), and by KT5823 (2 mM) or Rp-8-pCPT-
cGMPS (10 mM) (Figure 6A). On the other hand, following
treatment with the NO donor, NOR-3, which stimulatesNethe pathway downstream from the NMDAR and nNOS,
surface GluR1 increased even in the presence of AP5 or
nNOS inhibitor I, while ODQ, KT5823, or Rp-8-pCPT-
cGMPS still blocked the increase (Figure 6B).
To confirm the glycine-induced surface increase of
GluR1 using electrophysiology, we tested the effects of
nNOS inhibitor I, ODQ, KT5823, and Rp-8-pCPT-cGMPS
on glycine-induced enhancement in frequency and ampli-
tude of mEPSCs in the cultured hippocampal neurons.
Consistent with previous results (Lu et al., 2001), applica-
tion of glycine (200 mM, 3min) produced an immediate and
long-lasting increase in frequency (176.2% ± 19.7% of
baseline at 25 min after glycine application, n = 9) and
amplitude (136.2% ± 13.9% of baseline at 25 min after
glycine application, n = 9) of mEPSCs (Figures 6C–6E).
Perfusion of nNOS inhibitor I (10 mM), ODQ (10 mM),
KT5823 (2 mM), or Rp-8-pCPT-cGMPS (10 mM) blocked
glycine-induced enhancement of mEPSC frequency
(84.9% ± 32.2% [n = 6], 81.1% ± 22.3% [n = 5], 78% ±
22.2% [n = 8], and 86.6% ± 22.4% [n = 5] of baseline at
25 min for nNOS inhibitor I + glycine, ODQ + glycine,
KT5823 + glycine, and Rp-8-pCPT-cGMPS + glycine
groups, respectively; F(5,30) = 8.6, p < 0.001, two-way AN-
OVA with repeated-measures; Figures 6C and 6E) and
amplitude (89.7% ± 4.1%, 93.6% ± 5.2%, 89.9% ±
6.8%, and 97.6% ± 12.9% of baseline at 25 min for
nNOS inhibitor + glycine, ODQ + glycine, KT5823 + gly-
cine, and Rp-8-pCPT-cGMPS + glycine groups, respec-
tively; F(5,30) = 3.17, p < 0.001, two-way ANOVA with
repeated-measures; Figures 6D and 6E). Perfusion of
nNOS inhibitor I, ODQ, KT5823, or Rp-8-pCPT-cGMPS
alone did not affect basal mEPSC frequency and ampli-
tude (data not shown). These results support a model in
which NMDAR transmission activates cGKII via nNOS
and sGC activity, to increase AMPAR at the plasma
membrane.
LTP-inducing stimuli drive GluR1 to synapses (Hayashi
et al., 2000), and S845 phosphorylation plays a role in the
accompanying increase of GluR1 at the plasma mem-
brane (Esteban et al., 2003; Lee et al., 2003; Oh et al.,
2006). To validate our findings in the slice preparation,
we studied the role of the NO-cGMP-cGKII pathway in
LTP at the Schaeffer collateral-CA1 connection using hip-
pocampal slices. We found that LTP was dramatically
reduced when hippocampal slices were exposed to
nNOS inhibitor I (10 mM) for 20 min prior to tetanization
(114.57% ± 17.59% of baseline slope at 120 min after tet-
anus versus 228.42% ± 10.95% in vehicle-treated teta-
nized slices, n = 6 slices from 6 mice; F(1,10) = 24.30, p <
0.001; Figure 6F). nNOS inhibitor I alone did not affect
baseline transmission (103.12% ± 2.86% versus(F) Quantitation of surface/total ratio of HAGluR1 on neurons from experiments as the ones shown in (E). Bar graph shows mean ± SEM; n = 18 for
HAGluR1 WT, 20 for HAGluR1 R837A, and 16 for HAGluR1 R837E; **p < 0.01, ***p < 0.001.
(G) Quantitation of surface/total ratio of HAGluR1 R837A on neurons treated with saline (control), 8-Br-cGMP, or 8-Br-cAMP. Bar graph shows
mean ± SEM; n = 18 for control, 20 for 8-Br-cGMP, and 8-Br-cAMP; ***p < 0.001.
(H) Quantitation of surface/total ratio of HAGluR1 R837E on neurons treated with saline (control), 8-Br-cGMP, or 8-Br-cAMP. Bar graph shows
mean ± SEM; n = 20 for control, 17 for 8-Br-cGMP, and 16 for 8-Br-cAMP; ***p < 0.001.uron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 679
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cGKII Regulates GluR1 TraffickingFigure 6. Immunocytochemical and Electrophysiological Experiments on Cultures and Slices Validate a Model in which NMDAR
Transmission Activates cGKII via nNOS and sGC Activity, to Increase AMPARs at the Plasma Membrane
(A) Quantitation of surface levels of GluR1 in neurons treated with saline (control), glycine, or with glycine following pretreatment for 30 min with the
following inhibitors: AP5, nNOS inhibitor I, ODQ, KT5823, and Rp-8-pCPT-cGMPS. Bar graph showsmean ±SEM; n = 20 for each group; ***p < 0.001.680 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc.
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cGKII Regulates GluR1 Trafficking106.16% ± 5.22% in vehicle-treated nontetanized slices,
n = 4/4, F(1,6) = 0.22, p > 0.5, data not shown). Likewise,
a 10 min perfusion with an inhibitor of sGC, ODQ (10 mM),
suppressed LTP (94.88% ± 15.30% versus 210.91 ±
20.34 in vehicle-treated tetanized slices, n = 6/7, F(1,11) =
28.43, p < 0.001; Figure 6G). Treatment with ODQ did
notmodify baseline transmission (97.03%± 1.57% versus
100.15% ± 2.31% in vehicle-treated nontetanized slices,
n = 4/4, F(1,6) = 0.97, p > 0.1 compared to vehicle alone;
data not shown). When added to slices 10 min prior to tet-
anization, the cGKII inhibitor KT5823 (2 mM) also blocked
LTP (105.46% ± 11.94% versus 236.46% ± 10.96% in
vehicle-treated tetanized slices, n = 6/7, F(1,11) = 58.94, p <
0.0001, Figure 6H) without affecting baseline transmission
(97.03% ± 1.57% versus 101.24% ± 1.00% for the non-
tetanized slices either treated or not treated with the cGKII
inhibitor, n = 4/4, F(1,6) = 1.75, p > 0.1, data not shown).
Finally, 10 min perfusion of slice prior to tetanization with
the second specific cGKII inhibitor, Rp-8-pCPT-cGMPS
(10 mM), severely blocked LTP (106.59% ± 6.51% versus
234.15% ± 10.34% of baseline slope at 120 min after tet-
anus, n = 6/6, F(1,10) = 47.77, p < 0.0001, Figure 6I) without
affecting baseline transmission (96.71% ± 2.18% versus
102.91% ± 1.10% for the nontetanized slices either
treated or not treated with the cGKII inhibitor, n = 4/4,
F(1,6) = 2.90, p > 0.1, data not shown). These data suggest
a contribution of cGKII to LTP under our experimental
conditions.
Directly Disrupting cGKII-GluR1 Interaction
Affects Synaptic Plasticity
While two structurally different inhibitors for cGKII specif-
ically blocked cGMP induction of GluR1 phosphorylation
and surface increase, it is still possible that these inhibitors
could block other unexpected kinases. To disrupt the
cGKII-GluR1 interaction in neurons by a nonpharmacolog-
ical, kinase-specific approach, we expressed cGKII aa 1–
416, which contain the cGKII regulatory and cGMP-bind-
ing domains. This truncated regulatory domain fragmentNeuof cGKII was shown to have dominant-negative properties
and to block endogenous cGKII by interacting with theWT
cGKII catalytic domain, while not affecting the activity of
other kinases, including PKA and even the other cGK iso-
form, cGKI (Taylor et al., 2002). We fused this construct to
GFP (GFP-cGKII-i) and expressed it in neurons from
a Sindbis virus. As a control that GFP-cGKII-i binds en-
dogenous cGKII when virally expressed in neurons, we
showed that an antiserum against GFP coprecipitates
endogenous cGKII from neuronal lysates, when GFP-
cGKII-i, but not the control, GFP, is expressed, as ex-
pected (Figure 7A). Furthermore, upon expression in hip-
pocampal pyramidal cells, GFP-cGKII-i fills all neurites
and goes to spines (Figure 7B).
We then tested the effects of GFP-cGKII-i on GluR1 traf-
ficking. 8-Br-cGMP or 8-Br-cAMP increased the levels
of surface GluR1 in hippocampal neurons expressing
GFP (1 ± 0.19, untreated cells; 2.2 ± 0.26, 8-Br-cGMP,
p < 0.001; and 2.5 ± 0.31, 8-Br-cAMP, p < 0.001) (Figures
7C and 7D), consistent with previous results in uninfected
neurons. However, in neurons expressing GFP-cGKII-i,
8-Br-cGMP application did not increase levels of surface
GluR1 compared to untreated cells (surface GluR1, 1 ±
0.41 in untreated cells and 1 ± 0.17 in cells treated with
8-Br-cGMP, p > 0.05), while 8-Br-cAMP still induced an in-
crease in GluR1 surface expression (2.5 ± 0.33, p < 0.001,
compared to untreated) (Figures 7E and 7F), confirming
that GFP-cGKII-i specifically blocks cGMP-dependent
trafficking.
We next tested the effects of GFP-cGKII-i expression on
glycine-induced synaptic plasticity. Application of glycine
failed to increase either frequency (73.7% ± 13.5% of
baseline at 25 min after glycine application, n = 6, F(3,20) =
14.1, p < 0.001, two-way ANOVA with repeated-mea-
sures; Figures 8A and 8C) or amplitude (89.7% ± 6.8%
of baseline at 25 min after glycine application, n = 6,
F(3,20) = 2.6, p < 0.01, two-way ANOVA with repeated-
measures; Figures 8B and 8C) of mEPSCs in neurons ex-
pressing GFP-cGKII-i. However, application of glycine(B) Quantitation of surface levels of GluR1 in neurons treated with saline (control), NOR-3, or with NOR-3 following pretreatment for 30 min with the
following inhibitors: AP5, nNOS inhibitor I, ODQ, KT5823, and Rp-8-pCPT-cGMPS. Bar graph showsmean ± SEM; n = 20 for each group; ***p < 0.001.
(C and D) Average changes in frequency (C) and amplitude (D) of mEPSCs following application of vehicle (n = 3, open red circles), glycine (n = 9, filled
red circles), nNOS inhibitor I paired with glycine (n = 6, green squares), ODQ paired with glycine (n = 5, black squares), KT5823 paired with glycine (n =
8, blue squares), and Rp-8-pCPT-cGMPS paired with glycine (n = 5, filled blue squares). Application of glycine for 3 min produced a rapid and long-
lasting increase in frequency (p < 0.001) and amplitude of mEPSCs (p < 0.001). Perfusion of nNOS inhibitor I, ODQ, KT5823, and Rp-8-pCPT-cGMPS
blocked glycine-induced increase in frequency and amplitude of mEPSCs. The mean frequencies were 3.5 ± 0.8 Hz, 8.3 ± 0.9 Hz, 3.6 ± 0.9 Hz, 4.1 ±
0.7 Hz, 4.1 ± 0.5 Hz, and 3.7 ± 0.6 Hz for vehicle, glycine, nNOS inhibitor I + glycine, ODQ + glycine, KT5823 + glycine, and Rp-8-pCPT-cGMPS +
glycine groups, respectively. The mean amplitudes were 10.5 ± 0.5 pA, 14.7 ± 0.8 pA, 10.9 ± 0.6 pA, 11.1 ± 0.5 pA, 11.1 ± 0.7 pA, and 10.7 ± 0.6 pA
for vehicle, glycine, nNOS inhibitor I + glycine, ODQ + glycine, KT5823 + glycine, and Rp-8-pCPT-cGMPS + glycine groups, respectively. The thick
line represents the duration of glycine application, and error bars represent SEM.
(E) Cumulative probability distribution of mEPSC inter-event interval and mEPSC amplitude in vehicle (control), glycine, nNOS inhibitor I+glycine,
ODQ+glycine, KT5823+glycine and Rp-8-pCPT-cGMPS+glycine groups.
(F) LTP is strongly reduced by 20min perfusion with 10 mMnNOS inhibitor I (F(1,10) = 24.30, p < 0.001 compared to tetanized vehicle treated slices). The
horizontal bar indicates the period during which the drugwas added to the bath solution. In this and in the other figures the arrows indicate the tetanus
application. The insets show representative fEPSP before (continuous line) and after (dotted line) tetanus.
(G) The sGC inhibitor ODQ (10 mM) blocks LTP (F(1,11) = 28.43, p < 0.001 compared to vehicle + tetanus).
(H) Treatment with the cGK inhibitor KT5823 (2 mM) for 10 min impaired LTP (F(1,11) = 58.94, p < 0.0001, compared to vehicle + tetanus).
(I) Treatment with a second specific inhibitor for cGKII, Rp-8-pCPT-cGMPS (10 mM), for 10 min impaired LTP (F(1,10) = 47.77, p < 0.0001 compared to
vehicle + tetanus).ron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 681
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cGKII Regulates GluR1 TraffickingFigure 7. GFP-cGKII-i Blocks Trafficking of GluR1 in Hippocampal Neurons after Application of 8-Br-cGMP but Not 8-Br-cAMP
(A) Interaction of infected GFP-cGKII-i with endogenous cGKII in cultured neurons. Cells expressing GFP or GFP-cGKII-i were lysed and precipitated
with an anti-GFP Ab. The IPs and inputs were probed with an anti-cGKII Ab.
(B) Hippocampal cell in culture expressing GFP-cGKII-i and stained with an Ab that recognizes both cGKII-i and endogenous cGKII. Scale bar, 20 mm;
lower panel, 2 mm.
(C) Hippocampal neurons expressing control GFP (green) were treated with saline (control), 8-Br-cGMP, or 8-Br-cAMP. Neurons were stained live
for surface GluR1 (red). Scale bar, 4 mm.
(D) Quantitation of surface/total ratio of HAGluR1 on neurons from experiments as the ones shown in (C). Bar graph shows mean ± SEM; n = 15 for
control, 24 for 8-Br-cGMP, and 18 for 8-Br-cAMP; ***p < 0.001.
(E) Hippocampal neurons expressing GFP-cGKII-i (green) were treated with saline (control), 8-Br-cGMP, or 8-Br-cAMP. Neurons were stained live
for surface GluR1 (red). Scale bar, 4 mm.
(F) Quantitation of surface/total ratio of HAGluR1 on neurons from experiments as the ones shown in (E). Bar graph shows mean ± SEM; n = 15 for
control, 24 for 8-Br-cGMP, and 18 for 8-Br-cAMP; ***p < 0.001.significantly increased both frequency (217.5% ± 20.8%
of baseline at 25 min after glycine application, n = 6) and
amplitude (133.6% ± 4.8% of baseline at 25 min after gly-
cine application, n = 6) of mEPSCs in neurons expressing
control GFP protein (Figures 8A–8C). These results further
confirm the role of cGKII in NMDAR-mediated synaptic
plasticity and increase in AMPARs at the plasma mem-
brane.682 Neuron 56, 670–688, November 21, 2007 ª2007 Elsevier InTo confirm the role of cGKII in hippocampal LTP, we in-
fected mice with Sindbis virus expressing constructs for
GFP or GFP-cGKII-i. Cannulas were implanted bilaterally
into the dorsal hippocampi (Figure 8D). After 6–8 days,
mice were infused with the virus, and after 24 hr they
were sacrificed to prepare hippocampal slices. We con-
firmed by IB for GFP (Figure 8E) and by microscopy of
GFP fluorescence (Figure 8F) that the replacement proteinc.
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cGKII Regulates GluR1 Traffickingwas expressed in the hippocampal pyramidal cell layer of
the slices (Figure 8F). We did not find a difference in basal
synaptic transmission (BST) among mice injected with
vehicle or virus expressing the GFP or GFP-cGKII-i con-
structs (Figure 8G). BST was determined by measuring
the slope of the field excitatory postsynaptic potential
(fEPSPs) at increasing stimulus intensity in the different
groups. The slope of the input-output curve at stimulation
intensity equal to 35 V was94% of vehicle-injected mice
in GFP-infected mice and 96% in mice infected with
GFP-cGKII-i (vehicle: 1.09 ± 0.07 V/s, n = 6; GFP: 1.03 ±
0.12 V/s, n = 6; GFP-cGKII-i: 1.05 ± 0.18 V/s, n = 5). A
two-way ANOVA showed no difference between the three
groups (F(2,14) = 0.02, p = 0.98). However, in agreement
with results obtained using pharmacologic cGKII inhibi-
tors, slices with virus expressing the GFP-cGKII-i con-
struct showed an impairment of LTP when compared to
vehicle-treated slices (142.52% ± 17.37% of baseline
slope versus 242.05% ± 18.76, n = 6/6; F(1,10) = 10.15,
p = 0.01, Figure 8H). GFP expression did not affect LTP
(266.29% ± 35.02% of baseline slope, n = 6, F(1,10) =
0.77, p = 0.39, Figure 8H). Taken together, these data
demonstrate that the action of cGKII is required for synap-
tic plasticity in this system.
DISCUSSION
NMDAR stimulation activates nNOS and production of
NO, which results in cGMP production (Garthwaite,
1991; Hofmann et al., 2000) and cGKII activation. A major
mechanism for expression of NMDAR-dependent LTP
involves the synaptic insertion of GluR1 (Hayashi et al.,
2000; Malenka and Bear, 2004; Zamanillo et al., 1999).
Here we report that, following activation by the NMDAR,
cGKII binds to GluR1 and phosphorylates S845, leading
to an increase of GluR1 in the plasma membrane (Fig-
ure 8I). Notably, a cGKII dominant-negative inhibitor
peptide blocked the cGMP-dependent increase of GluR1
surface expression, prevented the increase in amplitude
and frequency of mEPSCs after chemLTP, and strongly
reduced LTP in hippocampal slices. These results demon-
strate a mechanism in which the NMDAR regulates
AMPAR trafficking during LTP via NO and cGKII.
Because NO is produced at postsynaptic sites
(Garthwaite and Boulton, 1995) and can diffuse through
lipid membranes, initial studies of NO-dependent plastic-
ity focused on presynaptic NO function through retro-
grade mechanisms (Bohme et al., 1991; O’Dell et al.,
1991; Schuman and Madison, 1991). Some results were
controversial, possibly because different methodologies
were employed (Bon and Garthwaite, 2001). Indeed,
cGMP derivatives only facilitate LTP maximally if briefly
applied when the NMDA receptor is active (Son et al.,
1998), and deviating protocols would lead to conflicting
results. More recently, the use of new NO donors and
NOS antagonists (Bon and Garthwaite, 2003; Puzzo
et al., 2005), both in vitro (Bon and Garthwaite, 2003)
and in vivo (Feil et al., 2005), has demonstrated a role ofNethe NO cascade in synaptic plasticity. Interestingly, as
reported here, both the sGC inhibitor ODQ and the cGK
inhibitor KT5823 were found to block LTP (Bon and
Garthwaite, 2001; Chien et al., 2003; Lu et al., 1999).
Nonetheless, specific molecular mechanisms underlying
the effects of NO, in particular in NO control of AMPAR
trafficking in LTP, have been wanting. S-nitrosylation of
NSF enhances NSF binding to GluR2 and regulates
GluR2 surface expression (Huang et al., 2005). Also, acti-
vation of the NO-cGMP-cGKI pathway increases both
GluR1 and synaptophysin puncta and the phosphorylation
of VASP in hippocampal neurons (Wang et al., 2005).
However, as yet, a specific pathway for NO control of
activity-dependent GluR1 trafficking to synapses, an es-
sential component of LTP, has not been reported. The
interaction of cGKII with GluR1 reported here, and its con-
sequent effect on GluR1 surface levels, directly link the
actions of NO to LTP via GluR1 trafficking.
Convergence of PKA and cGKII on S845
Phosphorylation
We report a physical association of cGKII with GluR1 that
enables the kinase to phosphorylate GluR1 at S845. This
phosphorylation is required for cGMP-dependent GluR1
surface accumulation, since block of the phosphorylation
by the S845A GluR1 mutation blocked the surface in-
crease. Others have shown that phosphorylation of S845
accompanies increases in GluR1 surface levels (Ehlers,
2000) and is necessary for GluR1 synaptic insertion during
LTP (Esteban et al., 2003). S845 is dephosphorylated dur-
ing hippocampal LTD (Lee et al., 1998, 2000), and S845
phosphorylation on its own is sufficient for increase of
GluR1 in the extrasynaptic plasma membrane (Oh et al.,
2006; Sun et al., 2005). Thus far only PKA phosphorylation
of S845 has been considered, perhaps because it was the
initial kinase shown to phosphorylate this site (Roche
et al., 1996). The present study demonstrates that cGKII
activity also phosphorylates S845.
Increases of surface GluR1 following both PKA and
cGKII phosphorylation are restricted to extrasynaptic sites
(Oh et al., 2006; Sun et al., 2005; and this report), and
AMPAR synaptic incorporation requires at least one addi-
tional step (Bredt and Nicoll, 2003; Passafaro et al., 2001;
Tardin et al., 2003), possibly mediated by S818 phosphor-
ylation (Boehm et al., 2006). Interestingly, although 8-Br-
cGMP on its own did not enhance hippocampal synaptic
responses, when paired with a weak tetanus that by itself
does not enhance responses, 8-Br-cGMP produced an
immediate potentiation (Zhuo et al., 1994). This suggests
that cGMP can prime the system for potentiation by
a weak tetanic stimulation, possibly by increasing the ex-
trasynaptic surface AMPAR population.
Differential Regulation of cGKII and PKA
The NMDAR and nNOS mutually interact with PSD-95
(Brenman et al., 1996; Christopherson et al., 1999), and
Ca2+ fluxes through the NMDAR activate nNOS in this
complex to produce NO (Bredt and Snyder, 1989;uron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 683
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cGMP, which activates cGKII. Ca2+ fluxes also stimulate
Ca2+-regulated adenylate cyclases (Wang and Storm,
2003), which produce cAMP, which activates PKA, which
also phosphorylates S845. PKA binds the A kinase an-
choring protein, AKAP79, which in turn binds the PDZ do-
main scaffolding protein, SAP97, which binds the GluR1
CTD, thus targeting PKA to the GluR1 CTD and facilitating
phosphorylation of S845 (Colledge and Scott, 1999).
Unlike the SAP97-AKAP-PKA pathway, the NO-cGMP-
cGKII pathway does not rely on a scaffold since the kinase
binds the receptor directly. Interestingly, a knockin mouse
expressing GluR1 that lacks the last 7 aa of its CTD and
does not bind SAP97 exhibited normal hippocampal LTP
and GluR1 trafficking (Kim et al., 2005). This is explained
if the NO-cGMP-cGKII pathway phosphorylates S845 in
this mutant.
GluR1 interacts with cGKII via auxiliary and core contact
CTD sequences that flank S845. Interestingly, a CTD con-
tact sequence resembles an AI domain sequence of
cGKII, suggesting that to bind the catalytic domain,
GluR1 mimics the AI domain (see Figure 8ii and Supple-
mental Discussion). Also, this receptor-kinase interaction
resembles the well-studied CaMKII binding to the NR2B
CTD (Lisman and McIntyre, 2001) (see Supplemental Dis-
cussion).
Mechanism of cGKII-Dependent GluR1 Trafficking
In the absence of cGMP, cGKII is inactive (Figure 8Ii). Fol-
lowing NMDAR stimulation, binding of cGMP to cGKII
induces a cGKII conformational change that causes AI
domain autophosphorylation, AI domain release from
the catalytic domain, and elongation of the kinase. The
GluR1 CTD binds the newly exposed cGKII catalytic do-Nemain, facilitating GluR1 phosphorylation and the increase
of surface GluR1. In one model for this increase, S845
phosphorylation promotes GluR1 trafficking to the plasma
membrane, perhaps by releasing ofGluR1 fromacytosolic
retention factor. Alternatively, GluR1 may cycle into and
out of the plasma membrane constitutively, and S845
phosphorylation may stabilize the receptor at the neuron
surface. With either model, S845 phosphorylation would
regulate the size of an extrasynaptic pool from which re-
ceptors may be inserted into the synapse during LTP.
Such transport may depend on additional GluR1 phos-
phorylation (Boehm et al., 2006). Because, as we have
shown, a highly selective peptide block of cGKII strongly
reduces LTP, such an increase in an extrasynaptic
receptor pool is likely to be a requirement for the synaptic
potentiation associated with LTP. The present work dem-
onstrates that the NMDAR can control the size of such
a receptor pool, acting through nNOS, NO, and cGMP
production and the activation of cGKII.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for details of themamma-
lian recruitment assay, 293T cell culture and GST pulldown, prepara-
tionand fractionation of cell extracts, in vitro phosphorylation experi-
ments, GluR1 phosphorylation in cortical cell cultures, and for Abs
and expression vectors used.
Yeast Two-Hybrid Screen
The GluR1 CTD cloned into the pSos vector was transformed into
yeast strain cdc25Ha (Stratagene) to screen an adult rat hippocampal
cDNA library in the pMyr (Stratagene) expression vector, using Cyto-
trap Vector Kit (Stratagene) according to the manufacturer’s instruc-
tions. Interaction of GluR1 CTD deletion mutants with cGKII were
similarly analyzed.Figure 8. Expression of GFP-cGKII-i Blocks Glycine-Induced Synaptic Plasticity in Cultured Hippocampal Neurons and LTP
in Hippocampal Slices
(A and B) Average changes in frequency (A) and amplitude (B) of mEPSCs following application of glycine (n = 9, filled red circles), GFP expression
paired with glycine (n = 6, green squares), GFP-cGKII-i expression paired with glycine (n = 6, black squares), and vehicle (control) (n = 3, open red
circles). Glycine application (3 min) produced a rapid and long-lasting increase in frequency (p < 0.001) and amplitude of mEPSCs (p < 0.001) in neu-
rons expressing GFP. However, expression of GFP-cGKII-i completely blocked glycine-induced increase in frequency and amplitude of mEPSCs.
The mean basal frequencies were 3.9 ± 0.5 Hz, 3.9 ± 0.6 Hz, 4.1 ± 0.6 Hz, and 3.5 ± 0.4 Hz for control, glycine, GFP + glycine, and GFP-cGKII-i +
glycine groups, respectively. The mean basal amplitudes were 9.8 ± 0.8 pA, 10.2 ± 0.8 pA, 10.8 ± 0.9 pA, and 9.8 ± 0.7 pA for control, glycine,
GFP + glycine, and GFP-cGKII-i + glycine groups, respectively. The thick line represents the duration of glycine application, and error bars represent
SEM.
(C) Cumulative probability distribution of mEPSC interevent interval andmEPSC amplitude in vehicle (control), glycine, GFP expression + glycine, and
GFP-cGKII-i expression + glycine groups.
(D) Cannulas were implanted bilaterally into the dorsal hippocampus (schematic representation).
(E) Lysates from uninfected hippocampus and hippocampus infected with GFP-cGKII-i were analyzed by IB using an anti-GFP Ab. IB for GFP
confirmed that slices infused with Sindbis virus carrying a construct for GFP-cGKII-i were infected.
(F) Representative examples of hippocampal slices viewed on a confocal microscope (203 objective) 24 hr after injection of Sindbis virus expressing
GFP-cGKII-i or vehicle. GFP is visible in the CA1 cell body area only in slices infected with GFP-cGKII-i (right panel).
(G) Basal synaptic transmission is not impaired in animals injected with GFP-cGKII-i virus compared to slices from animals injected with GFP virus or
vehicle (F(2,14) = 0.02, p = 0.98).
(H) The GFP-cGKII-i virus impaired LTP (F(1,10) = 10.15, p = 0.01, compared to vehicle) whereas GFP virus did not affect LTP (F(1,10) = 0.77, p = 0.39,
compared to vehicle).
(Ii) Model for the regulation of GluR1 trafficking by cGKII. Based on the lipid raft location of the kinase and the fact that GluR1 surface levels are
increased after S845 phosphorylation, the kinase is depicted at the plasma membrane and the receptor intracellularly, before S845 phosphorylation.
However, the subcellular locations of the kinase and the receptor at the time of phosphorylation have not yet been established. See Discussion. (Iii)
cGKII autoinhibitory domain homology with GluR1 CTD binding site for cGKII. GluR1 S845 and cGKII S126 (red) and homologous residues (blue) are
shown.uron 56, 670–688, November 21, 2007 ª2007 Elsevier Inc. 685
Neuron
cGKII Regulates GluR1 TraffickingNeuronal Cell Culture and Immunocytochemistry
Hippocampal primary culture, Sindbis virus preparation, neuronal in-
fection, and immunostaining of endogenous and recombinant proteins
have been described (Osten et al., 2000). Details are described in the
Supplemental Experimental Procedures.
Image Analysis and Quantitation
Images were acquired using a Nikon PCM 2000 confocal microscope,
and analysis was done blind using ImageJ software. Images for all ex-
perimental groups were taken using identical acquisition parameters.
With images acquired for quantitation, background image intensity
was determined and subtracted by thresholding during image acquisi-
tion. To analyze surface expression of HAGluR1 and the different
HAGluR1 mutants, the ratio of surface signal to total signal was calcu-
lated. To analyze surface expression of endogenous GluR1, neuritic
fractions located one soma diameter from the soma were selected,
and fluorescence was quantified using ImageJ software. Approxi-
mately five neuritic fractions from each cell were taken for analysis.
GluR1-SV2 colocalization analysis was done using the Colocalization
Threshold plugin from ImageJ software. The Manders’ overlap coeffi-
cient was used as the indicator of the proportion of GluR1 signal (red
channel) coincident with the SV2 signal (green channel) over its total
intensity (Manders et al., 1992). Error bars are standard errors of the
mean, and significance was determined by the t test.
Electrophysiological Experiments
Both patch-clamp experiments and slice recording have been previ-
ously described (O’Dell et al., 1991; Puzzo et al., 2005). Patch-clamp
recordings were performed 10–15 days after plating cell cultures,
whereas slices were obtained from 3-month-old male mice (C57BL6;
The Jackson Laboratory). The details of these techniques are reported
in the Supplemental Experimental Procedures.
Slice Infection
Mice were anesthetized with 20 mg/kg Avertin and implanted with
a 26-gauge guide cannula into the dorsal part of the hippocampi (co-
ordinates: p = 2.4 mm, L = 1.5 mm to a depth of 1.3 mm) (Paxinos,
1998). The cannulas were fixed to the skull with acrylic dental cement
(Paladur). The infusion was made after 6–8 days through infusion can-
nulas that were connected to a microsyringe by a polyethylene tube.
The entire infusion procedure took 1 min, and animals were handled
gently to minimize stress. Either vehicle or Sindbis virus carrying con-
structs for GFP or GFP-cGKII-i were injected bilaterally in a volume of
1 ml over 1 min. After injection, the needle was left in place for another
minute to allow diffusion.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/56/4/670/DC1/.
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